Manufacturer record
Nabros Pharma Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Nabros Pharma Pvt. Ltd were declared Not of Standard Quality between March 2026 and April 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: NR019, Nifedipine Sustained Released Tablet IP (exp Oct 2026). FDL, Vadodara (state lab) found it not of standard quality: Dissolution. Listed in the April 2026 alert.
Records by type
2 records linked to Nabros Pharma Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Nifedipine Sustained Released Tablet IP | Batch NR019Mfg Nov 2024 · Exp Oct 2026 | DissolutionDissolution | FDL, VadodaraState lab | Apr 2026 |
| Nifedipine Sustained Released Tablet IP | Batch NR019Mfg Nov 2024 · Exp Oct 2026 | DissolutionDissolution | FDL, VadodaraState lab | Mar 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.